These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 17611557)

  • 1. Pleiotropic p27(Kip1), BCR-ABL and leukemic stem cell: the trio in concert.
    Sengupta A; Banerjee S
    Leukemia; 2007 Dec; 21(12):2559-61. PubMed ID: 17611557
    [No Abstract]   [Full Text] [Related]  

  • 2. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
    Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I
    Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular biology of chronic myeloid leukemia.
    Maru Y
    Int J Hematol; 2001 Apr; 73(3):308-22. PubMed ID: 11345196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The Philadelphia chromosome: from the gene to therapeutic methods].
    Pérez-Losada J; González-Sarmiento R; Sánchez-García I
    Sangre (Barc); 1998 Apr; 43(2):127-35. PubMed ID: 9656774
    [No Abstract]   [Full Text] [Related]  

  • 5. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
    Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chronic granulocytic leukemia (Ph+): among yesterday's myeloproliferative syndromes, today's chronic myeloid leukemias, and tomorrow's mature-element monocellular myelopathies].
    Sánchez Fayos J; Prieto E; Chica Gullón E
    Sangre (Barc); 1998 Apr; 43(2):121-6. PubMed ID: 9656773
    [No Abstract]   [Full Text] [Related]  

  • 7. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
    Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
    Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment.
    Clarkson B; Strife A
    Leukemia; 1993 Nov; 7(11):1683-721. PubMed ID: 8231240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The molecular biology of chronic myeloid leukaemia.
    Melo JV
    Leukemia; 1996 May; 10(5):751-6. PubMed ID: 8656667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
    Sengupta A; Banerjee D; Chandra S; Banerjee S
    J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-ABL insufficiency for the transformation of human stem cells into CML.
    Matioli GT
    Med Hypotheses; 2002 Nov; 59(5):588-9. PubMed ID: 12376083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic versus acute myelogenous leukemia: a question of self-renewal.
    Jamieson CH; Weissman IL; Passegué E
    Cancer Cell; 2004 Dec; 6(6):531-3. PubMed ID: 15607956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcr-abl-positive and -negative clonogenic cells in CML patients undergoing long-term interferon treatment.
    Wandl UB; Bützler R; Niederle N; Kloke O; Mengelkoch B; Becher R; Seeber S; Opalka B
    Leukemia; 1994 May; 8(5):776-9. PubMed ID: 7514245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C/EBPdelta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation.
    Gery S; Tanosaki S; Hofmann WK; Koppel A; Koeffler HP
    Oncogene; 2005 Feb; 24(9):1589-97. PubMed ID: 15674331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear topography and expression of the BCR/ABL fusion gene and its protein level influenced by cell differentiation and RNA interference.
    Bártová E; Harnicarová A; Pacherník J; Kozubek S
    Leuk Res; 2005 Aug; 29(8):901-13. PubMed ID: 15978941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the C-terminal actin binding domain in BCR/ABL-mediated survival and drug resistance.
    Underhill-Day N; Pierce A; Thompson SE; Xenaki D; Whetton AD; Owen-Lynch PJ
    Br J Haematol; 2006 Mar; 132(6):774-83. PubMed ID: 16487179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.
    Melo JV; Deininger MW
    Hematol Oncol Clin North Am; 2004 Jun; 18(3):545-68, vii-viii. PubMed ID: 15271392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
    Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV
    Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
    Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
    Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The fundamental prevalence of chronic myeloid leukemia-generating clonogenic cells in the light of the neutrality theory of evolution.
    Jankovic GM; Pavlovic M; Vukomanovic DJ; Colovic MD; Lazarevic V
    Blood Cells Mol Dis; 2001; 27(5):913-7. PubMed ID: 11783955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.